

JPN JOURNAL OF PSYCHOSOCIAL NURSING[®]

AND MENTAL HEALTH SERVICES


April 2016 Volume 54, Number 4

Cited in MEDLINE/PubMed

Healio[®] ACCESS FULL TEXT
at Healio.com/JPN




Sensory modulation

Measuring efficacy on a psychiatric inpatient unit



LATUDA helps your patients with bipolar depression experience more of life's everyday moments

Latuda[®]
(lurasidone HCl) tablets
20mg | 40mg | 60mg | 80mg | 120mg



Look inside for more information

INDICATIONS AND USAGE

LATUDA is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

IMPORTANT SAFETY INFORMATION FOR LATUDA

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.

CONTRAINDICATIONS

LATUDA is contraindicated in the following:


- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
- Strong CYP3A4 inducers (e.g., rifampin)

WARNINGS AND PRECAUTIONS

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS):

NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. Please see additional Important Safety Information, including **Boxed Warning**, and Brief Summary of Prescribing Information on inside pages.



Pharmacology Focus

- 18** Product Update
- 19** Clip & Save: Drug Chart
Alzheimer's Disease
- 22** Safety and Abuse Liability
of Oxazepam: Is This
Benzodiazepine Drug
Underutilized?
Robert H. Howland

Original Articles

- 31** Text Messaging for Psychiatric
Outpatients: Effect on Help-Seeking
and Self-Harming Behaviors
A mobile phone intervention program promoted
help-seeking behaviors by sending text messages for
6 months.
*Toyohiko Kodama, Hiroko Syouji, Sachiko Takaki,
Hirokazu Fujimoto, Shinichi Ishikawa, Masaaki Fukutake,
Masaru Taira, and Takeshi Hashimoto*
- 38** Reflective Prompts to Guide
Termination of the Psychiatric Clinical
Student Nursing Experience
A clinically focused learning activity using structured
prompts helped psychiatric nursing students'
experiences with the process of termination.
Grace B. Hubbard
- 44** Sensory Modulation Treatment on a
Psychiatric Inpatient Unit
Sensory modulation treatment was effective in
reducing the number of restraints and seclusions on
inpatient psychiatric units, as well as decreasing self-
perceived arousal levels.
Jennifer Gardner

Sections

- 13** Editorial
- 15** News
- 16** Adolescents Who Self-Injure
Simone C. Durand and Teena M. McGuinness
- 52** CNE Quiz
- 55** NARSAD Art